On March 2, Uzbekistan received another shipment of the hepatitis C medication, Sofosbuvir-400mg, from Egypt, as reported by Dunyo News Agency. The consignment contained 6,720 units of the drug, packed in 12 boxes, which will be distributed to patients at the Research Institute of Virology under the Ministry of Health of Uzbekistan.
An agreement has been established with the Egyptian government for the transfer of a total of 800,000 units of Daclatasvir and Sofosbuvir, drugs used in the treatment of hepatitis C, and Entecavir, used against hepatitis B, to Uzbekistan by 2025. The total cost of this agreement is $4.2 mn. As of today, 13.4 tonnes of these drugs have already been delivered to Uzbekistan.
Experts estimate that a full three-month course of treatment requires three packs each of Daklatasvir and Sofosbuvir. While the average cost of this treatment course in Egypt is $31, it was estimated at $100 in Uzbekistan until this year. The provision of 800,000 units of medication from Egypt is expected to benefit approximately 133,000 patients, resulting in significant cost savings for Uzbekistan’s healthcare system.
The funds saved from procuring medications at lower costs are anticipated to be redirected towards expanding population screening for hepatitis. This initiative aims to increase the number of individuals screened from the current 10,000 to 1 mn, enabling the identification of viruses and facilitating the eradication of the disease.
Follow Daryo's official Instagram and Twitter pages to keep current on world news.
Comments (0)